Item 5. Market for Registrant’s Common Equity
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Effective May 2012, our common stock was approved
for quotation on the OTC Bulletin Board under the ticker symbol “MAGE.” The Company’s shares are now quoted on the OTCQB
of the OTC Markets Group, Inc. The following sets forth the high and low trading prices for the periods shown:
2021
2022
High
Low
High
Low
First quarter ended March 31
$ 1.15
$ 0.86
$ 0.53
$ 0.26
Second quarter ended June 30
$ 1.10
$ 0.77
$ 0.29
$ 0.06
Third quarter ended September 30
$ 1.33
$ 0.79
$ 0.30
$ 0.10
Fourth quarter ended December 31
$ 1.01
$ 0.42
$ 0.21
$ 0.12
The closing price of the Company's common stock
as of July 11, 2023 was $0.17, as reported on the OTC.QB. The OTC.QB prices are bid and ask prices which represent prices between broker-dealers
and do not include retail mark-ups and mark-downs or any commissions to the broker-dealer. The prices do not reflect prices in actual
transactions. As of July 11, 2023 there were approximately 90 record owners of the Company's common stock.
The
OTC.QB is a registered quotation service that displays real-time quotes, last sale prices and volume information in over-the-counter
(OTC) securities. An OTC equity security generally is any equity that is not listed or traded on NASDAQ or a national securities exchange.
The OTCQB is not an issuer listing service, market or exchange. Although the OTCQB does not have any listing requirements, per se, to
be eligible for quotation on the OTCQB, issuers must remain current in their filings with the SEC or applicable regulatory authority.
Our Board of Directors may declare and pay dividends
on outstanding shares of common stock out of funds legally available therefore in its sole discretion; however, to date, no dividends
have been paid on common stock and we do not anticipate the payment of dividends in the foreseeable future.
Trading in our common stock is subject to rules
adopted by the SEC regulating broker dealer practices in connection with transactions in "penny stocks." Those disclosure rules
applicable to penny stocks require a broker dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver
a standardized risk disclosure document prepared by the SEC. That disclosure document advises an investor that investment in penny stocks
can be very risky and that the investor's salesperson or broker is not an impartial advisor but rather paid to sell the shares. The disclosure
contains further warnings for the investor to exercise caution in connection with an investment in penny stocks, to independently investigate
the security, as well as the salesperson with whom the investor is working and to understand the risky nature of an investment in this
security. The broker dealer must also provide the customer with certain other information and must make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. Further,
the rules require that, following the proposed transaction, the broker provide the customer with monthly account statements containing
market information about the prices of the securities.
Recent Sales of Unregistered Securities
The following is a summary of sales of unregistered
securities undertaken by the Company. The share, per share and price per share information have been adjusted to give retroactive effect
to the Reverse Split.
24
2021
(a) On
February 10, 2021, the Company issued 266,667 common shares as a commitment fee. The shares were valued at $0.92, the closing price of
the Company’s stock on February 10, 2021. During the year ended December 31, 2021, the Company recognized $245,334 of stock-based
compensation related to this issuance.
(b) On
August 6, 2020, the Company entered into a one-year investor relations consulting agreement. As consideration for its services under the
Agreement, the Company agreed to pay to the consultant 261,538 restricted shares of the Company’s common stock. The shares were
valued at $1.56, the closing price of the Company’s stock on August 6, 2020. As of December 31, 2020, the Company had not issued
the shares and accrued $136,000 related to this agreement. During the year ended December 31, 2021, the Company issued the 261,538 shares
related to this agreement, settled the prior year accrual of $136,000 for 2020 services and recognized $272,000 of stock-based compensation
for services provided during the year ended December 31, 2021.
(c) During
the year ended December 31, 2021, the Company received net proceeds of $10,000 from the exercise of 50,000 warrants. On July 15, 2020,
the Company issued 500,000 shares for services rendered pursuant to two investor relations agreements: 200,000 shares under a Services
Agreement and 300,000 shares under a Consulting Agreement. The shares were valued at $1.29, the closing price of the Company’s stock
on July 15, 2020.
(d)
In June 2021, the Company issued an aggregate of 2,278,813 shares of common stock in consideration of (i) the conversion of an aggregate
of 192,269 shares of Series A Preferred Stock and (ii) an aggregate of $356,123 in accrued interest on the Series A Preferred Stock. The
shares were issued to two investors, each of whom qualified as an “accredited investor” within the meaning of Rule 501(a)
of Regulation D under the Securities Act. The securities, which were taken for investment and were subject to appropriate transfer restrictions,
were issued without registration under the Securities Act in reliance upon the exemption provided in Section 4(a)2 and Rule 506(b) of
Regulation D under the Securities Act.
2022
(e) During
the year ended December 31, 2022, the Company issued 646,668 common shares as deferred financing costs. The shares were valued at a price
ranging from $0.24 - $0.30, the closing price of the Company’s stock at issuance. During the year ended December 31, 2022, the Company
recognized $180,000 of deferred financing costs related to this issuance.
Unless otherwise noted, all of the foregoing transactions
were undertaken in reliance upon the exemption contained in Section 4(a)(2) of the Securities Act of 1933.
INCENTIVE COMPENSATION
Equity Incentive Plan
Effective September 1, 2017, the Equity Incentive
Plan was approved by written consent of stockholders holding 75% of the Company’s outstanding common stock and was adopted by the
Board of Directors. The Company is authorized to grant rights to acquire up to a maximum of 200,000 shares of common stock under the Plan,
giving retroactive effect to the Reverse Split. The Plan is authorized to grant incentive stock options that qualify under Section 422
of the Internal Revenue Code of 1986, as amended.
The 2017 Plan provides for the grant of (1) both
incentive and nonstatutory stock options, (2) stock bonuses, (3) rights to purchase restricted stock and (4) stock appreciation rights
(collectively, "Stock Awards"). Incentive stock options granted under the 2017 Plan are intended to qualify as "incentive
stock options" within the meaning of Section 422 of the Code. Nonstatutory stock options granted under the 2017 Plan are intended
not to qualify as incentive stock options under the Code.
25
Arrangements with CEO
Effective August 1, 2020, the Company and Michael
Lavigne, executed a Restricted Stock Unit Agreement pursuant to which the Company agreed to grant to Mr. Lavigne, in consideration of
services to be rendered as President, CEO and Director, restricted stock units consisting of 15,000 units for each month of service. The
vested stock units will be settled in shares of common stock upon or as soon as practicable (a) upon written request any time after December
31, 2020 or (b) following the termination date, whichever occurs first. As of December 31, 2022 and 2021, 435,000 and 255,000 restricted
stock units may be settled in shares of common stock, respectively. During the years ended December 31, 2022 and 2021, the Company recognized
$35,888 and $162,465 of stock-based compensation related to the agreement, respectively.
ITEM 6.
SELECTED FINANCIAL DATA
We are a smaller reporting company as defined by the Exchange Act and
are not required to provide the information required under this item.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.